Efficacy of Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy: A Pilot Study.

ABSTRACT: Background/Objectives: Chronic central serous chorioretinopathy (cCSC) is a vision-threatening disorder characterized by persistent subretinal fluid (SRF). While several treatment options exist, their efficacy varies, and optimal management remains uncertain. This retrospective pilot study aimed to evaluate the efficacy and safety of intravitreal brolucizumab in patients with symptomatic cCSC without pachychoroid neovasculopathy (PNV). Methods: In total, 15 eyes of 15 patients diagnosed with symptomatic cCSC without PNV were treated with a single intravitreal injection of brolucizumab. Patients were followed for six months. Primary outcomes included resolution of SRF and changes in central subfield thickness (CST) and subfoveal choroidal thickness (SCT). Best-corrected visual

SUBMITTER: Hwang S 

PROVIDER: S-EPMC12470493 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature